1. Repository of OAI
Ελληνικά   English  
Saved Searches

Discover

Search


Current filters:

Clear current filters  or Add more filters

View Option


Results 21-30 of 41 (Search time: 0.008 seconds).

  Dose-dependent Effect of Rosuvastatin Treatment on HDL-subfraction Phenotype in Patients With Primary Hyperlipidemia (Journal article)

  Effect of Non-Statin Lipid Lowering and Anti-Obesity Drugs on LDL Subfractions in Patients with Mixed Dyslipidaemia (Journal article)

  Thyroid substitution therapy induces high-density lipoprotein-associated platelet-activating factor-acetylhydrolase in patients with subclinical hypothyroidism: a potential antiatherogenic effect (Journal article)

  Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin (Journal article)

  Plasma Visfatin Concentration Is a Marker of an Atherogenic Metabolic Profile (Journal article)

  Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures (Journal article)

  Plasma PAF-acetylhydrolase(Lp-PLA(2)) activity as a marker of small-dense LDL in subjects at median cardiovascular risk (Journal article)

  The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome (Journal article)

  The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia (Journal article)

  The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia (Journal article)